Trial Profile
A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary) ; Pramipexole
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms SUSTAIN
- Sponsors Boehringer Ingelheim
- 26 Jun 2023 Results assessing proportion of participants treated with once-weekly semaglutide, or a comparator, achieving a metabolic composite target endpoint from SUSTAIN trials (1 - 5 and 7 - 10) and SUSTAIN China presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 23 Jan 2020 Status changed from active, no longer recruiting to completed.
- 18 Jan 2020 Planned End Date changed from 16 Jan 2020 to 9 Jan 2020.